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AbstrACt
Introduction Effective management of seasonal and 
pandemic influenza is a high priority internationally. 
Guidelines in many countries recommend antiviral treatment 
for older people and individuals with comorbidity at 
increased risk of complications. However, antivirals are not 
often prescribed in primary care in Europe, partly because 
its clinical and cost effectiveness has been insufficiently 
demonstrated by non-industry funded and pragmatic 
studies.
Methods and analysis Antivirals for influenza-Like Illness? 
An rCt of Clinical and Cost effectiveness in primary CarE is 
a European multinational, multicentre, open-labelled, non-
industry funded, pragmatic, adaptive-platform, randomised 
controlled trial. Initial trial arms will be best usual primary 
care and best usual primary care plus treatment with 
oseltamivir for 5 days. We aim to recruit at least 2500 
participants ≥1 year presenting with influenza-like illness (ILI), 
with symptom duration ≤72 hours in primary care over three 
consecutive periods of confirmed high influenza incidence. 
Participant outcomes will be followed up to 28 days by 
diary and telephone. The primary objective is to determine 
whether adding antiviral treatment to best usual primary care 
is effective in reducing time to return to usual daily activity 
with fever, headache and muscle ache reduced to minor 
severity or less. Secondary objectives include estimating cost-
effectiveness, benefits in subgroups according to age (<12, 
12–64 and >64 years), severity of symptoms at presentation 
(low, medium and high), comorbidity (yes/no), duration of 
symptoms (≤48 hours/>48–72 hours), complications (hospital 
admission and pneumonia), use of additional prescribed 
medication including antibiotics, use of over-the-counter 
medicines and self-management of ILI symptoms.
Ethics and dissemination Research ethics committee 
(REC) approval was granted by the NRES Committee South 
Central (Oxford B) and Clinical Trial Authority (CTA) approval 
by The Medicines and Healthcare products Regulatory 
Agency. All participating countries gained national REC and 
CTA approval as required. Dissemination of results will be 
through peer-reviewed scientific journals and conference 
presentations.
trial registration number ISRCTN27908921; Pre-
results.
strengths and limitations of this study
 ► Antivirals for influenza-Like Illness? An rCt of Clinical 
and Cost effectiveness in primary CarE (ALIC4E) will 
be the first publicly funded, multicountry, pragmatic 
study determining whether antivirals should be rou-
tinely prescribed for influenza-like illness in primary 
care, and if prespecified characteristics (age, symp-
tom duration, illness severity and comorbidities) in-
fluence outcomes.
 ► The platform design allows the study to remain rel-
evant to evolving circumstances, with the ability to 
add treatments arms.
 ► Response adaptation allows the proportion of par-
ticipants with key characteristics allocated to study 
arms to be altered during the course of the trial 
according to emerging outcome data, so that par-
ticipants’ information will be most useful, and in-
creasing their chances of receiving the intervention 
that will be most effective for them.
 ► Since the possibility of taking a placebo influences 
participant expectation about their treatment and 
determining effects of the interventions on patient 
behaviour in real-world care is critical to estimates 
of cost effectiveness, ALIC4E is designed as an 
open-labelled trial.
 ► The open design carries risk of bias in participants’ 
self-reported outcomes; clear explanation of equi-
poise by recruiters may mitigate this.
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bACkground
The influenza virus is highly contagious and represents 
a common cause of respiratory infection with local and 
systemic symptoms. Annual influenza epidemics account 
for considerable morbidity and mortality,1–4 and influ-
enza outbreaks have the potential to become pandemics.2 
Effective control and management of seasonal and 
pandemic influenza is a high priority for national govern-
ments. Routine use of antiviral agents is rare in European 
primary care.5 General practitioners (GPs) in Europe 
generally advise patients who consult with influen-
za-like illness (ILI) to take paracetamol or non-steroidal 
anti-inflammatory drugs, either as required or at regular 
intervals. They may also provide advice about other over-
the-counter (OTC) medicines and self-management of 
ILI symptoms, for example, maintaining fluids, bed rest 
and taking time off work or school. This broad approach 
is currently considered best usual care for the empirical 
management of ILI in Europe.6–8 
Currently, the most suitable antiviral agent available 
for pragmatic evaluation in Antivirals for influenza-Like 
Illness? An rCt of Clinical and Cost effectiveness in primary 
CarE (ALIC4E) is oseltamivir (Tamiflu), a neuraminidase 
inhibitor (NI). The US Food and Drug Administration 
approved oseltamivir in 1999. Oseltamivir was classified 
by WHO as an essential medicine until 2017,9 10 and many 
countries have stockpiles of the drug to ensure it is readily 
available to treat seasonal and pandemic influenza.5 Osel-
tamivir could therefore be used for the management of 
ILI on assumption that many cases of ILI may be caused 
by influenza, the probability of this being higher during 
confirmed periods of heightened influenza based on 
national reports of ILI consultations and laboratory-con-
firmed influenza cases.
Oseltamivir phosphate is an oral prodrug which 
undergoes hydrolysis by hepatic esterase to form active 
oseltamivir carboxylate. Oseltamivir carboxylate acts by 
selective inhibition of influenza A and B viral neuramini-
dases. This enzyme normally promotes release of the virus 
from infected cells by cleaving terminal sialic acid resi-
dues on the surface of host cells and influenza virus enve-
lopes and facilitates viral movement within the respiratory 
tract. By blocking the activity of the enzyme, oseltamivir 
prevents new viral particles from being released.11 12 
Oseltamivir might also modify the immune response to 
influenza infection by reducing levels of proinflamma-
tory cytokines which might, in turn, modulate symptoms 
of influenza.13
Industry-sponsored trials (or studies), efficacy studies 
and clinical study reports of NIs, most often oseltamivir, 
have been the subject of many systematic reviews and 
meta-analyses, including individual patient meta-anal-
yses.14–16 In two recent meta-analyses that differed in their 
methods and the primary outcome measures used, but 
that included almost the same set of trials, Jefferson et al 
found that oseltamivir improved the mean time to first 
alleviation of symptoms over the placebo by 16.8 hours,13 
and Dobson et al found that oseltamivir improved the 
median time to alleviation of all symptoms over the 
placebo by 17.8 hours15. The reviewers also found that 
oseltamivir reduced the risk of self-reported, non-ver-
ified pneumonia but not for clinically diagnosed pneu-
monia.13 15 Dobson et al furthermore indicated that 
treatment with oseltamivir might reduce the risk of lower 
respiratory tract infection complications and hospitalisa-
tion in patients testing positive for influenza.15 However, 
increased nausea and vomiting were found to be associ-
ated with oseltamivir use.13 15 Even with a possible reduc-
tion in symptom duration (compared with a placebo), 
the value of oseltamivir treatment of previously healthy 
individuals with non-severe seasonal influenza is ques-
tionable. Conversely, circumstances of some individuals, 
for example, those urgently needing to return to work 
and parents and other carers, may mean that a reduction 
in function-limiting symptoms of a day may be considered 
very worthwhile. The UK Academy of Medical Sciences 
recently reviewed current evidence, and they advised that 
additional pragmatic trials in primary care and cost-effec-
tiveness analyses that take virulence and severity of the 
circulating strain into account are required to further 
inform such judgements.17
Since 1999, oseltamivir has generated sales in excess 
of US$18bn (£11bn; €13bn). The USA stockpiled 
65 million treatments at a cost of US$1.3bn. The UK 
spent £424m on a stockpile of 40 million doses. By 2009, 
96 countries possessed enough oseltamivir for 350 million 
people.18 In 2017, WHO downgraded oseltamivir in the 
list of essential medicines from a ‘core’ drug to one that 
is ‘complimentary’—a category of drugs considered 
less cost-effective.9 10 However, there has never been a 
large-scale, international, publicly funded, pragmatic 
randomised controlled trial (RCT) of its cost-effective-
ness in primary care, and so the evidence base either 
to support or not support the routine use of this agent 
in primary care is inadequate and raises the question: 
does the effect found in previous efficacy studies trans-
late into a meaningful benefit in every day primary care? 
Specifically, what are the overall costs and benefits of this 
possible shortened symptom duration from the perspec-
tive of the individual sufferer, the health services and for 
society? Do patients considered to be at higher risk for 
complications of influenza (for example, due to age, dura-
tion and severity of symptoms or relevant comorbidity) 
benefit more from antiviral treatment in primary care? 
Answering these questions will reduce important clinical 
uncertainty for primary care clinicians about whether to 
prescribe antiviral agents for ILI and whether or not to 
prioritise antiviral treatment for subgroups of primary 
care patients.
The ALIC4E trial will be delivered as work package 4 
of the Platform for European Preparedness Against (Re-) 
emerging Epidemics (PREPARE: www. prepare- europe. 
eu/) consortium grant. PREPARE is a European Commis-
sion funded network for the rapid and efficient delivery of 
harmonised, large-scale clinical research studies on infec-
tious diseases.19 ALIC4E will be an RCT of investigational 
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medicinal products in primary care that will determine 
the clinical-effectiveness and cost-effectiveness of adding 
antiviral agents to best usual primary care for patients 
with specific characteristics suffering from ILI, and thus 
enable clinicians to better individualise prescribing 
decisions.
The primary objective of ALIC4E is therefore to deter-
mine whether adding antiviral treatment to best usual 
primary care is effective in reducing time taken to return 
to usual daily activity in patients with ILI. Secondary 
objectives will be to determine whether antiviral treat-
ment is cost-effective; benefits prespecified subgroups 
of participants; decreases hospital admissions; decreases 
complications related to ILI, especially pneumonia; 
improves the health-related quality of life; decreases 
(repeat) attendance at the GP, or other health services, 
decreases time to first reduction, time to alleviation and 
new/worsening of ILI symptoms; reduces the use of OTC 
and prescribed medication, including antibiotics, and 
affects the self-management of ILI symptoms.
MEthods/dEsIgn
The protocol for ALIC4E is reported according to the 
Standard Protocol Items Recommendations for Interven-
tional Trials (SPIRIT) guidelines.
Ethics and dissemination
All participants will provide written informed consent 
before participation. The study will be conducted (using 
Good Clinical practice guidelines) according to the prin-
ciples of the Declaration of Helsinki and in accordance 
with other relevant national guidelines, regulations and 
acts. An independent Data Monitoring Committee will 
review efficacy and safety data by treatment allocation, 
and a Trial Steering Committee (TSC)will provide over-
sight of the trial.
A manuscript with the results of the primary outcome 
will be published in a peer-reviewed journal. Additional 
manuscripts will report secondary outcomes and be 
submitted for publication in peer-reviewed journals.
Patient and public involvement
The relevance and necessity of the research question, 
study design and development of patient facing docu-
ments including the consent forms, participant infor-
mation sheets, symptom diary, all follow-up forms and 
promotional materials have been reviewed by members 
of the public. The patient and public involvement group 
included a mixture of research experienced and inexperi-
enced people, parents and elderly members of the public.
As part of the TSC, a representative of the relevant 
patient group is involved in the continued review of the 
recruitment to and conduct of the study. A TSC meeting is 
held at least once per year before each recruiting season.
The intervention arm in ALIC4E is the use of an anti-
viral in addition to best usual primary care. The burden 
to participants was assessed by the TSC and considered 
minimal as the only antiviral currently being assessed 
in ALIC4E, oseltamivir, is a licensed medication with 
marketing authorisation globally. In the context of the 
ALIC4E trial, a standard dose of oseltamivir has been 
shown to be well tolerated. The study itself is only using the 
standard dose of oseltamivir and is being used according 
to the marketing authorisation it has been granted.
Trial participants will not be informed of the trial 
results directly. However, the results will be published on 
the PREPARE Consortium website (http://www. prepare- 
europe. eu/) and on the Nuffield Department of Primary 
Care website (https://www. phc. ox. ac. uk/ phctrials), both 
can be accessed freely.
networks and participants
ALIC4E is a European multinational, multicentre, 
open-labelled, pragmatic, adaptive-platform, RCT. Twen-
ty-one primary care clinical research networks in 15 Euro-
pean countries will recruit participants (figure 1), and 
each network will co-ordinate the recruiting sites within 
their network. A number of the primary care research 
networks had already established collaborations through 
the Genomics to combat Resistance against Antibiotics in 
Community-acquired LRTI in Europe (www. grace- lrti. org) 
Network of Excellence.20 21 They were sustained through 
Translational Research on Antimicrobial resistance and 
Community-acquired infections in Europe (www. esf. org/ 
trace) and were complemented by PREPARE for ALIC4E 
with six additional primary care research networks.
Recruitment will be over three consecutive influenza 
seasons, Q4 2015 to Q1/2 2018. Each season’s start and 
end of recruitment will be based on reports of local ILI 
incidence rising above (or falling below) prespecified 
thresholds, using information supplied by the European 
Centre for Disease Prevention and Control (ECDC)22 and 
local and regional sources for each network.
We aim to recruit a minimum of 2500 participants 
through recruiting sites (GP practice, primary care out 
of hours (OOH) service or paediatric centres within 
primary care). Potential participants will be identified 
when they present to the recruiting sites with symptoms 
of ILI, or when they telephone for an appointment or 
advice about their symptoms. Participants must meet the 
inclusion criteria (including symptom onset of 72 hours 
or less) and have none of the exclusion criteria (table 1). 
The definition of ILI used in ALIC4E was based on the 
ECDC definition23 with flexibility to maximise recruit-
ment of children and the elderly.24 25 If eligible and willing 
to participate, the participant will complete the rest of the 
initial trial procedures either within the same visit, or at 
a second appointment with a recruiter at the recruiting 
site, or at home.
The local implementation of the trial has built-in flex-
ibility, and local network recruitment processes vary. For 
example, medical students may assist with recruitment 
tasks in certain practices, whereas others will incorporate 
triage systems or additional trial-specific clinics and/or 
research support staff in their recruitment processes.
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randomisation and blinding
After obtaining informed, written consent, participants 
will be randomised at the point of care using a remote 
online electronic data capture system (research online 
2). Emergency randomisation procedures will be avail-
able should this web-based facility be temporarily unavail-
able. Randomisation will initially be a 1:1 ratio between 
the two arms, with stratification by subgroup according to 
ECDC definitions of those at higher risk of complications 
from influenza, namely their age (<12, 12–64 and >64 
years), severity of symptoms (low, medium and high), any 
relevant comorbidityi (yes/no) and duration of symptoms 
i Heart disease/diabetes/chronic respiratory condition (eg, asthma, 
chronic obstructive pulmonary disease)/hepatic, hematological, neuro-
logical or neurodevelopmental condition/stroke or transient ischaemic 
Figure 1 ALIC4E European networks. Coordinating centres are in Oxford, UK and Utrecht, The Netherlands. The ALIC4E 
recruiting networks include: Belgium (Antwerp and Ghent), Czech Republic, Denmark, France, Greece, Hungary, Ireland, 
Lithuania, Netherlands, Norway, Poland (Bialystok and Lodz), Spain (Barcelona, Catalonia and Santiago de Compostela), 
Sweden, Switzerland and the UK (Oxford, Southampton and Cardiff). ALIC4E, Antivirals for influenza-Like Illness? An rCt of 
Clinical and Cost effectiveness in primary CarE; GRACE, Genomics to combat Resistance against Antibiotics in Community-
acquired LRTI in Europe. 
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since onset (≤48 hours/>48–72 hours). The proportions 
randomised to study arms may be altered during the 
course of the trial following a prespecified Bayesian, 
response adaptive approach.26
ALIC4E is an open trial. The participant, the 
recruiting clinician and the study personnel will be 
aware of the participant’s allocation. An open prag-
matic trial was chosen because this design is better for 
determining effects in routine care when patients are 
much less tightly supervised. Estimates of effect from 
placebo-controlled efficacy trials may not translate into 
similar effect sizes when interventions are taken up 
into routine clinical care. Knowledge of what medica-
tion one is taking influences help-seeking behaviour, 
and decisions to reconsult may substantially affect 
cost-effectiveness. In addition, efficacy estimates have 
already been repeatedly determined in efficacy trials 
with tightly controlled inclusion criteria, in which chil-
dren, the elderly and people with comorbidities have 
been under-represented.27 Clinicians do not prescribe 
placebos in routine care, and so the credible compar-
ator is current best practice.28 Therefore, no unblinding 
or code breaking is required in the event of a relevant 
emergency. However, the trial team will be blind to treat-
ment allocation at the aggregate level. The recruiter 
will promote equipoise for the participant about the 
attack/overnight hospital admission in the last year.
two arms which will be carefully covered in trial-specific 
training, and each arm of the trial will be supported 
as in routine practice; previous open pragmatic trials 
have been able to minimise placebo effects using this 
approach.29 30
Intervention
Participants randomised to best usual primary care plus 
oseltamivir arm will be given a dose of 75 mg oseltamivir 
two times per day for 5 days by the oral route (capsules) 
for those ≥13 years. For those who are ≥1 year but <13 
years, the doses will be two times per day for 5 days in 
suspension, administered orally, according to weight: 
10–15 kg=30 mg, >15–23 kg=45 mg, >23–40 kg=60 mg and 
>40 kg=75 mg. Children weighing >40 kg and who are able 
to swallow capsules may receive treatment with the adult 
dosage of 75 mg capsules two times per day for 5 days as 
an alternative to the same dose of oseltamivir suspension. 
Route of administration, dosage and treatment periods 
follow the manufacturer’s summary of product charac-
teristics.12 Weight will be measured in children ≤12 years 
during the recruitment visit for medication dosing. All 
other participants will be asked about their weight at the 
baseline assessment and measured in case of uncertainty. 
A daily symptom diary and subsequent day 14–28 tele-
phone call will be used to monitor intervention compli-
ance, and together with a telephone call after day 28, will 
also ascertain a minimal data set for some other outcomes.
Table 1 Eligibility criteria
Inclusion Exclusion
 ► Male or female, aged at least 1 year
 – Presenting with ILI in primary care 
during a period of increased influenza 
activity. ILI=sudden onset of self-
reported fever, with at least one 
respiratory symptom (cough, sore 
throat, running or congested nose) and 
one systemic symptom (headache, 
muscle ache, sweats or chills or 
tiredness), with symptom duration of 
72 hours or less
 ► Is able and willing to comply with all trial 
requirements
 ► Participant or legal guardian(s) of a 
child is willing and able to give informed 
consent
 ► Agrees not to take antiviral agents apart 
from study antiviral agents according to 
patient randomisation
 ► Chronic renal failure, for example, known or estimated creatinine glomerular 
filtration rate <60 mL/min (known=recorded in participant’s clinical records)
 ► Condition or treatment associated with significant impaired immunity 
(eg, long-term oral steroids, chemotherapy or immune disorder) 
(known=recorded in participant’s clinical records)
 ► Those who in the opinion of the responsible clinician should be prescribed 
immediate antiviral treatment
 ► Allergic to oseltamivir or any other trial medication
 ► Scheduled elective surgery or other procedures requiring general anaesthesia 
during the subsequent 2 weeks
 ► Participant with life expectancy estimate by a clinician to be less than 
6 months
 ► Patient with severe hepatic impairment
 ► Responsible clinician considers urgent hospital admission is required
 ► Any other significant disease or disorder which, in the opinion of the 
responsible clinician, may either put the participants at risk because of 
participation in the trial, may influence the result of the trial or may affect the 
participant’s ability to participate in the trial
 ► Involvement, including completion of any follow-up procedures, in another 
clinical trial of an investigational medicinal product in the last 90 days
 ► Previous Antivirals for influenza-Like Illness? An rCt of Clinical and Cost 
effectiveness in primary CarE trial participation
 ► Patients unable to be randomised within 72 hours after onset of symptoms
 ► Requirement for any live viral vaccine in the next 7 days
 – Optional according to specific country legislation:Pregnant, lactating or 
breastfeeding women
ILI, influenza-like illness.
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Endpoints
The primary outcome is patient reported time to having 
both returned to usual daily activity, and ‘fever’, ‘head-
ache’ and ‘muscle ache’ symptoms all rated as ‘≤minor 
problem’. For non-verbal children, ‘clinginess’ will 
replace ‘headache’ and ‘muscle ache’, when both are 
unanswered.
Secondary outcomes will include (collected up to day 
28):
 ► cost-effectiveness measures through healthcare 
resource use and health-related quality of life
 ► effectiveness in subgroups of participants (based on 
age bands, initial illness severity, relevant comorbidity, 
duration of symptoms and laboratory-confirmed 
influenza A/B positivity)
 ► hospital admissions (overnight stay)
 ► (re-) attendance at GP practice, hospital emer-
gency care, primary care OOH services or paediatric 
centres
 ► complications related to ILI and/or potential relevant 
complications such as pneumonia
 ► time to first reduction, time to alleviation of and new/
worsening ILI symptoms
 ► use of prescription medications, including antibiotics
 ► use of OTC medications
 ► participant reported self-management and usual daily 
activities.
Procedures and assessments
Table 2 outlines the ALIC4E schedule of procedures 
according to the SPIRIT guidelines.
Baseline assessment (day 1)
After obtaining written, informed consent, recruiters 
will complete a baseline case report form (CRF). This 
will include the required information for randomisation: 
age; relevant comorbidities; duration of symptoms and 
clinician’s rating of severity of ILI as mild, moderate or 
severe. In addition, the CRF will ascertain participant’s/
parent’s severity grading for: fever, running or congested 
nose, sore throat, headache, cough, shortness of breath, 
muscle ache and pains, sweats/chills, diarrhoea, nausea 
and/or vomiting, abdominal pain, low energy/tired, not 
sleeping well, dizziness, feeling generally unwell (grad-
ing=no, minor, moderate and major problem); informa-
tion about any usual care advice given to the participant 
and type of healthcare coverage (eg, public, private or 
mixed). The symptom questions will be supplemented 
with child-specific questions so that the Canadian Acute 
Respiratory Illness Influenza Scale will be completed for 
children ≤12 years.31
Additionally, clinical examination findings will be 
recorded including: temperature and the way it was 
measured (oral, ear or axilla), use of antipyretics in the 
last 4 hours, pulse rate, weight (≤12 years or in cases of 
uncertainty), height, smoking status, gender and whether 
they have had influenza vaccination within 6 months and 
pneumococcal vaccination within 5 years.
The recruiter will provide antiviral medication 
according to the participant’s group allocation and stan-
dardised instructions on how to take the medication. The 
recruiter will also take an oropharyngeal and a nasal swab 
(COPAN) from those <16 years and a nasopharyngeal 
swab (COPAN) from those ≥16 years. All swabs will be 
placed in 3 mL universal transport media and transported 
to a local laboratory for storage. Finally, they will instruct 
participants how to complete the symptom diary and give 
information about telephone follow-up assessments.
Diary (day 1–14) and follow-up
There is no requirement for participants to attend a face-
to-face follow-up visit as part of their study participation, 
as all subsequent measurements will be ascertained by 
self-completed diary-based questionnaires and through 
telephone calls from the local trial team.
Participants (or their legal guardian or their carer) will 
be asked to complete a symptom diary from day 1 (base-
line) to day 14 after randomisation. The following data 
points will be collected once: expectations of treatment 
Table 2 ALIC4E schedule of procedures
Screening
Baseline 
day 1
Day 
1–14
Day 
14–28
Post 
day 28
Eligibility 
assessment*
✓
Informed 
consent*†
✓
Baseline CRF* ✓
Physical 
examination*
✓
Swab(s)* ✓
Randomisation* ✓
Dispensing of trial 
drugs*
✓
Symptom diary† ✓
Day 2–4 phone 
call‡
✓
Day 14–28 phone 
call‡
✓
After day 28 
phone call‡
✓
Clinical notes 
review§‡
✓
Adverse event 
assessments‡
✓ ✓
SAE follow-up‡ ✓ ✓
*Completed by recruiter.
†Completed by participant, includes standardised written health-
related quality of life assessment and documents resource use.
‡Completed by trial team (Chief Investigator/Principal Investigator/
coordinator), day 28 call includes standardised verbal health-
related quality of life assessment.
§Country dependent.
ALIC4E, Antivirals for influenza-Like Illness? An rCt of Clinical and 
Cost effectiveness in primary CarE; CRF, case report form; SAE, 
serious adverse event.
 o
n
 13 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021032 on 12 July 2018. Downloaded from 
7Bongard E, et al. BMJ Open 2018;8:e021032. doi:10.1136/bmjopen-2017-021032
Open access
benefit, ethnicity, employment status, cohabitation, preg-
nancy and stage and current long-term medication. The 
following data points are collected daily in the diary: 
severity of selected ILI symptom, quality of life (EuroQol 
Visual Analogue Scale (VAS)), return to usual daily 
activity, prescription medication use (including antibi-
otics), use of OTC medication or remedies, adherence to 
trial medication and potential side effects (up to day 7). 
The following data points will be collected weekly: quality 
of life (using EQ-5D-5L index (respondents >12 years) or 
EQ-5D-3Y (respondents ≤12 years)), effect of the partic-
ipants’ symptoms on usual daily activities, healthcare 
resource use, out-of-pocket expenditure and ILI state of 
people in the same household.
Participants and legal guardians will be telephoned on 
day 3 (±1 day) (with day 1 defined as the day they were 
recruited into the study) to offer support with symptom 
diary completion and to check for any urgent issues. 
They will also be telephoned on day 14 (up to day 28) 
and asked on what day they returned to their usual 
daily activity, if and when their fever, headache and 
muscle ache symptoms reduced to minor severity or less 
to ensure the primary endpoint is collected for all partic-
ipants and to ascertain any serious adverse events (SAEs) 
in the preceding 2 weeks. Participants will receive a final 
telephone call on or after day 28 to complete a verbal 
EQ-5D-5L/3Y and VAS, to answer remaining questions 
about symptom resolution if needed and about their trial 
participation and consent process as part of a process 
evaluation (see below). The trial team will ask whether 
participants have had a recurrence of their symptoms 
during this time and whether they have been admitted 
into hospital as a result of their symptoms.
Participants who have visited the hospital with compli-
cations possibly related to ILI and who have had a chest 
X-ray will have their primary care clinical records exam-
ined by the trial team for confirmation of relevant diag-
noses of complications, including pneumonia.
Laboratory testing and point of care test
Once the swabs have been received at local laboratories, 
samples will be frozen and stored at −70°C (−20°C is 
acceptable if there is no deep freezer). After each influ-
enza season, samples will be transported to the Laboratory 
of Medical Microbiology, University of Antwerp, Belgium 
for analysis. Each participant’s swab(s) will be analysed 
using a Multiplex RT-PCR for detection of pathogen 
genes by TaqMan technology to identify whether or not 
the participant is infected with influenza A or B, with 
other respiratory virusesii or with bacteriaiii.
ii Rhinovirus, coronavirus (NL63/229E/OC43/HKU1), parainfluenza 
(1, 2, 3, 4), human metapneumovirus A/B, bocavirus, respiratory syncy-
tial viruses A/B, adenovirus, enterovirus, parechovirus.
iii Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, 
Haemophilus influenzae type B, Staphylococcus aureus.
Interviews and qualitative assessment
As part of the day 28 telephone call to the participants 
or legal guardians or carers, questions will be asked 
about motivation for participating in the ALIC4E study, 
what influenced that decision and questions related to 
research participation during a pandemic.
All participating clinicians will be asked to complete a 
brief questionnaire, and a subsample will be asked their 
perspectives on the trial process, their views of influ-
enza management in primary care and participation in 
pandemic research.
Safety and discontinuation or withdrawal of participants from trial 
treatment
Oseltamivir has a well-documented safety profile and is 
a commonly used medication in a primary care setting. 
As a result, no non-SAEs will be recorded in this study. 
All SAEs occurring during the 28 days participants are 
enrolled on the trial will be recorded. It will be left to the 
investigator’s clinical judgement to decide whether or not 
a symptom or side effect is of sufficient severity to require 
the participant’s removal from treatment. If the partic-
ipant is withdrawn due to an adverse event (AE), the 
investigator will arrange for follow-up visits or telephone 
calls until the AE has resolved or stabilised or until the 
end of their trial participation, whichever is later. If the 
participant is withdrawn due to an AE, follow-up data will 
continue to be collected, and their information will be 
included for the purpose of the intention to treat (ITT) 
analysis. Participants have the right to withdraw from the 
study at any time without any prejudice to current and 
future healthcare.
response adaptive-platform trial design
An ‘adaptive platform trial’ enables multiple interventions 
for the same indication to be tested simultaneously within 
a master protocol and often includes the capacity to add, 
or drop, study arms while the study is in progress.32 33 Plat-
form trials provide an effective framework to study patient 
heterogeneity in outcomes, with the goal of determining 
the best treatment for various subgroups of patients. In 
addition, platform trial designs can incorporate response 
adaptive randomisation in order to randomise more 
participants to the best performing interventions during 
the course of the trial. This can increase statistical power 
and efficiency of the trial, as well as lead to better patient 
outcomes over the course of the study.34
We chose an adaptive platform trial design because it 
provided flexibility to evaluate additional interventions in 
the trial, should interventions emerge that are suitable 
to pragmatic evaluation in primary care. Additionally, 
the design provides the ability to prospectively identify 
particular subgroups of interest that may receive benefit 
from antiviral agents, as opposed to estimating a single 
overall effect. This is done by incorporating a Bayesian 
modelling approach, combined with response adaptive 
randomisation based on prespecified participant charac-
teristics. There will be multiple interim analyses during 
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recruitment; planned after every 750 patients and/or 
between influenza seasons.
In ALIC4E, participants will be initially randomised 
in a 1:1 ratio to the two arms, with stratification by 
subgroup and random blocks. Each arm will maintain 
at least a 10% probability of randomisation within 
each subgroup throughout the course of the trial. Arm 
superiority will be assessed by subgroup and may be 
declared superior in some subgroups, but not within 
others. If, at an interim analysis, an arm meets the 
superiority criterion for one of the treatments, rando-
misation probabilities may be modified for those 
subgroups such that a minimum of 10% of participants 
are allocated to the inferior arm, with the remaining 
allocation to the superior arm (a maximum of 90%, 
if two arms). In this event, stratification and blocking 
will no longer occur within these subgroups. This will 
ensure that the majority of participants receive the 
best-known therapy, yet the trial design will still allow 
the assessment of seasonal variation and population 
changes in the study population over time. In addi-
tion, we will still be able to collect data about costs 
and health-related behaviours (including healthcare 
seeking) associated with a poorly performing arm.
New comparator arms may enter the trial as determined 
by the TSC. Eligible therapies will include newly approved 
treatments for ILI or therapies recommended by public 
health agencies during an influenza pandemic. If an arm 
is added to the trial, there is a prespecified algorithm 
determining randomisation ratios, and for activating 
response adaptive randomisation within subgroups to the 
respective treatment arms. The operating characteristics 
of the trial will be updated via simulation; however, the 
general structure of the trial does not change. Response 
adaptive randomisation may be activated in subgroups 
without satisfying superiority criterion only if the number 
of interventions is greater than two.
Justification of sample size
A sample size calculation for the planned design is not 
available using traditional formulas. Instead, simulations 
must be used to estimate the operating characteristics of 
the adaptive algorithm, including estimates of how many 
participants with particular characteristics are required in 
order to detect differences in treatments. In these simula-
tions, the prespecified algorithm will be applied such that 
the randomisation of participants with particular prespec-
ified characteristics will depend on the number of arms 
and the collected outcome data. In addition, the algo-
rithm will determine when arms are dropped for futility, 
when an intervention is declared superior, and will have 
a process for adding a new intervention to the platform 
trial.
Between 2500 and 4500 participants will be recruited 
during three consecutive winters. This range has been 
chosen to ensure sufficient power for comparisons in 
the overall population, as well as within the prespecified 
subgroups. Given the nature of the study’s adaptive design 
and the desire to ensure sufficient power for multiple 
hypotheses across several subgroups, the number of 
participants needed to be recruited is a complex multi-
dimensional calculation. Hence, numerous simulations 
were conducted to calculate power under various plau-
sible scenarios. The maximum target of 4500 participants 
was chosen from these simulations because it gave over 
80% power for many of the subgroup analyses with a 
1-day benefit in terms of symptoms relief from oseltamivir. 
Of the participants, 2500 will provide over 99% power 
for comparing the primary endpoint in the overall study 
population where there is at least a 1-day benefit of osel-
tamivir for participants with confirmed influenza. This 
number will also provide >80% power for all subgroups 
if there is a 2-day benefit of oseltamivir in participants 
with confirmed influenza. We based these simulations on 
the assumption that 50% of patients will have confirmed 
influenza and 50% of patients will have ILI originating 
from another viral infection.
Statistical analysis
The primary analysis will be ITT and will include all 
randomised participants in the treatment arm they were 
assigned regardless of treatment taken. Secondary anal-
yses will include the subset of the ITT population with 
confirmed influenza. There will be at least one interim 
analysis when accrual and data collection for each season 
is complete and before recruitment opens in the subse-
quent influenza season. If accrual is rapid and large 
numbers of patients are enrolled, for example, in the 
case of influenza pandemic, more than one interim anal-
ysis may be conducted during an influenza season, each 
occurring after approximately an additional 750 patients 
have been enrolled. The adaptive randomisation proba-
bilities may be updated and arms assessed for superiority 
after each interim analysis.
The composite primary endpoint of return to usual 
activities with resolution of any fever, muscle ache and 
headache to a minor problem or less will be modelled 
according to a Bayesian piece-wise exponential 
model. This is a survival time model that allows the 
baseline hazard to vary across follow-up. The hazard 
for reaching the primary endpoint will be modelled 
during four time intervals—0–2 day, 3–5 days, 6–10 
days and 11 or more days. Participants not reaching 
the primary endpoint by 28 days (including partici-
pants that die) will be considered censored at 28 days. 
Participants who withdraw, are lost to follow-up or not 
evaluated for the primary endpoint for any reason will 
be considered censored at their last contact date or 28 
days, whichever is earlier.
Cost-effectiveness analysis
Cost-effectiveness analysis will compare the direct medical 
costs and health outcomes (in terms of number of days 
where ILI limits usual activities and in terms of quality 
adjusted life years gained) between the different arms. 
The analysis will use data from the trial (resource use, 
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EQ-5D-5L, EQ-5D-3Y and VAS scores) and other rele-
vant data from the countries in which the trial is set (eg, 
unit costs and type of healthcare provided within each 
country). Potential differences in repeated measures 
(EQ-5D-5L, EQ-5D-3Y and VAS) between arms will be 
investigated on a per-participant basis using mixed-effects 
models. Valuation of quality of life (using a standardised 
instrument for measuring generic health status) will be 
done in accordance with the guidelines of the Euroqol 
group,35 using the ‘EQ-5D-5L Crosswalk Index Value 
Calculator’.
Uncertainty will be explored using bootstrapping to 
represent clouds of incremental cost-effectiveness ratios 
on the cost-effectiveness plane, as well as cost-effective-
ness acceptability curves. Subgroup analyses will be 
performed to acknowledge heterogeneity within each 
arm of the trial (eg, age, severity and country). Value of 
perfect information analysis may also be performed to 
identify which sources of uncertainty should be reduced 
through additional research to efficiently improve deci-
sion making.
dIsCussIon
The ALIC4E trial will be the first large-scale, inter-
national, non-industry-sponsored, pragmatic, 
randomised trial of (cost-)effectiveness of adding osel-
tamivir to best usual primary care for people suffering 
from ILI.
ALIC4E will be an open trial in order to approxi-
mate effects in conditions close to those of usual care 
in order to determine real-world estimates of (cost-) 
effectiveness. Open trials have been criticised because, 
should a treatment appear beneficial, it may not be 
clear if the effect resulted from biological mechanism 
or because of a placebo effect. When considering the 
possible outcomes of ALIC4E, if no benefit is found in 
the antiviral arm, despite the comparator usual care 
arm not being enhanced by the possible effects of a 
placebo, then prescribing the antiviral agent should 
not be recommended. On the other hand, if a benefit 
from an antiviral agent is identified in the pragmatic 
trial, given that the drug’s efficacy will have already 
been demonstrated in many placebo-controlled trials 
and that the drug’s mechanisms of action are known 
and are specific to the condition under study, then it 
would be obtuse to suggest that any benefit ALIC4E 
may identify derives from the placebo effect, and not 
from the antiviral’s effect on influenza.
The lack of cost-effectiveness analyses alongside clinical 
trials, and given that children, older people and people 
with comorbidities are under-represented in studies that 
have been done, has once again been highlighted after 
the WHO’s decision to downgrade the status of osel-
tamivir.9 36 Despite the lack of trial evidence, the 2017 
WHO Model List of Essential Medicines states that the 
use of oseltamivir should be restricted to severe illness 
due to confirmed or suspected influenza virus infection in 
critically ill hospitalised patients.10 Another report quoting 
the WHO states: “unless new information supporting the 
use in seasonal and pandemic outbreaks is provided, the 
next Expert Committee might consider oseltamivir for 
deletion”.9 The current UK and US guidelines recom-
mend treatment of defined subgroups of frail patients 
and patients with increased risk for complications.6 37 
Since the evidence base for these recommendations is 
incomplete, withholding treatment from these or other 
patients may possibly deny them benefit. By including a 
‘best usual primary care’ arm, our study will determine 
the added benefit of antiviral agents over and above 
current practice for seasonal and potentially pandemic 
influenza. This information will be of great importance 
to the delivery of primary care for ILI, as well as enhance 
the evidence base around advocating self-care. In many 
countries, patients with ILI symptoms are advised not to 
consult but to self-manage, and patients with additional 
risk factors are seldom routinely treated with an antiviral 
agent. This is largely because of an absence of evidence 
about the cost-effectiveness overall and in subgroups of 
interest.
The virulence, spread and type of circulating influ-
enza strains vary from season to season. ALIC4E aims 
to recruit over three winter/influenza seasons in 15 
countries, thereby obtaining widely applicable data 
allowing us to determine whether any benefit or 
otherwise of antiviral agents is influenced by season. 
Furthermore, the aim is to include a wide age-range 
of participants from many different settings, as well 
as those with comorbidities. Additionally, in the event 
of an influenza pandemic, or should additional inter-
vention arms be included, a decision could be made 
to increase the maximum sample size.
The adaptive design offers several advantages over a 
traditional study design. Recruitment into a particular 
arm can be stopped once a predetermined level of 
certainty about the effectiveness or non-effectiveness 
of treatment in that arm has reached a predefined 
estimated precision. Adaptive randomisation could 
increase the chances of participants being allocated 
to arms where their information will be most useful 
and to the intervention that is most effective for 
them. This can lead to better patient care and better 
patient outcomes as the trial progresses. Second, the 
platform design allows new intervention arms to be 
added to the trial, benefiting from comparisons with 
existing treatment arms in a head to head way. This 
flexibility extends to a potential pandemic situation 
where additional or alternative interventions may be 
added according to governmental or public health 
recommendations. In this way, the study will remain 
current and relevant to clinical practice and evolving 
circumstances throughout.
ALIC4E will be novel in many ways. It will provide crit-
ical information about the clinical and cost-effectiveness 
of adding oseltamivir to best current ILI management in 
conditions that approximate usual care, both overall, as 
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well as in important, prespecified subgroups. ALIC4E is 
likely therefore to enhance the evidence base supporting 
and important and common area of clinical practice.
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